Companies sponsors |
Autolus (obecabtagene autoleucel) |
Others |
Department of Health and Social Care |
|
NHS England |
Patient carer groups |
African Caribbean Leukaemia Trust |
|
Anthony Nolan |
|
Black Health Agency for Equality |
|
Blood Cancer UK |
|
Cancer 52 |
|
Cancer Black Care |
|
Cancer Equality |
|
Chronic Lymphocytic Leukaemia Support Association |
|
DKMS |
|
Helen Rollason Cancer Charity |
|
Independent Cancer Patients Voice |
|
Kevin Kararwa Leukaemia Trust |
|
Leukaemia Cancer Society |
|
Leukaemia Care |
|
Leukaemia UK |
|
Macmillan Cancer Support |
|
Maggie’s Centres |
|
Marie Curie |
|
South Asian Health Foundation |
|
Specialised Healthcare Alliance |
|
Tenovus Cancer Care |
|
WMUK |
Professional groups |
Association of Anaesthetists |
|
Association of Cancer Physicians |
|
Association of Surgeons of Great Britain and Ireland |
|
British Blood Transfusion Society |
|
British Geriatrics Society |
|
British Institute of Radiology |
|
British Oncology Pharmacy Association |
|
British Psychosocial Oncology Society |
|
British Society for Haematology |
|
British Society of Blood and Marrow Transplantation and Cellular Therapy |
|
British Transplantation Society |
|
British Society of Interventional Radiology |
|
Cancer Research UK |
|
NHS Blood and Transplant |
|
Royal College of General Practitioners |
|
Royal College of Nursing |
|
Royal College of Pathologists |
|
Royal College of Physicians |
|
Royal College of Radiologists |
|
Royal Pharmaceutical Society |
|
Royal Society of Medicine |
|
Society and College of Radiographers |
|
UK Clinical Pharmacy Association |
|
UK Oncology Nursing Society |
Associated public health groups |
Public Health Wales |
|
UK Health Security Agency |
Comparator companies |
AAH Pharmaceuticals (dasatinib, imatinib) |
|
Accord UK (cytarabine, filgrastim, fludarabine, imatinib, pegfilgrastim |
|
Amarox (imatinib) |
|
Amgen (blinatumomab, filgrastim, pegfilgrastim) |
|
Aurobindo (Milpharm) (imatinib) |
|
Chugai Pharma UK Ltd (lenograstim) |
|
Cipla EU (imatinib) |
|
Dr. Reddy’s Laboratories (imatinib) |
|
Hospira UK (cytarabine) |
|
Incyte Biosciences UK (ponatinib) |
|
Mylan (dasatinib) |
|
Napp Pharmaceuticals (pegfilgrastim) |
|
Novartis (imatinib, tisagenlecleucel) |
|
Pfizer (cytarabine, filgrastim, idarubicin, inotuzumab ozogamicin) |
|
Sandoz (dasatinib, filgrastim, imatinib, pegfilgrastim) |
|
Sanofi (fludarabine) |
|
Teva UK (dasatinib, fludarabine, lipegfilgrastim) |
|
Viatris UK Healthcare (dasatinib) |
|
Zentiva (dasatinib) |
General commentators |
All Wales Therapeutics and Toxicology Centre |
|
Allied Health Professionals Federation |
|
Board of Community Health Councils in Wales |
|
British National Formulary |
|
Care Quality Commission |
|
Department of Health, Social Services and Public Safety for Northern Ireland |
|
Healthcare Improvement Scotland |
|
Hospital Information Services –Jehovah’s Witnesses |
|
Medicines and Healthcare products Regulatory Agency |
|
National Association of Primary Care |
|
National Pharmacy Association |
|
NHS Blood and Transplant |
|
NHS Confederation |
|
Scottish Medicines Consortium |
|
Welsh Government |
|
Welsh Health Specialised Services Committee |
Relevant research groups |
Cochrane Haematological Malignancies Group |
|
Genomics England |
|
Institute of Cancer Research |
|
Leukaemia Busters |
|
Lymphoma Research Trust |
|
MRC Clinical Trials Unit |
|
National Institute for Health Research |